Non-immunosuppressive treatment for IgA nephropathy (Q24235956)

20 October 2023

6

Giovanni FM Strippoli

author given names

Giovanni Fm

author last names

Strippoli

1 reference

20 October 2023

2

Peggy M Cawthon

Peggy M

Cawthon

1 reference

20 October 2023

5

Donald A Molony

Donald A

Molony

1 reference

20 October 2023

Sharon Reid

1

Sharon

Reid

1 reference

21412884

20 October 2023

Joshua A Samuels

series ordinal

4

author given names

Joshua A

author last names

Samuels

1 reference

21412884

Cochrane Database of Systematic Reviews

20 October 2023

publication date

16 March 2011

0 references

published in

0 references

cites work

Treatment of severe IgA nephropathy with omega-3 fatty acids: the effect of a "very low dose" regimen.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Vitamin E therapy in IgA nephropathy: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Effects of co-administration of urokinase and benazepril on severe IgA nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Clinical observation on treatment of IgA nephropathy with Huobahuagen Tablets and irbesartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Prednisolone co-administered with losartan confers renoprotection in patients with IgA nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intend

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension--a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Angiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Telmisartan is more effective than losartan in reducing proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN62574616]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Can young adult patients with proteinuric IgA nephropathy perform physical exercise?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

A comparison of corticosteroid and warfarin therapy in IgA nephropathy with crescent formation: preliminary trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Sodium sensitivity of blood pressure appearing before hypertension and related to histological damage in immunoglobulin a nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Diclofenac, a nonsteroidal anti-inflammatory drug, decreases proteinuria in some glomerular diseases: a controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Grading quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Immunosuppressive agents for treating IgA nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

An "evidence-based" survey of therapeutic options for IgA nephropathy: assessment and criticism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

IgA nephropathy: a disease in search of a large-scale clinical trial to reliably inform practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Non-immunosuppressive treatment for IgA nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

Efficacy of tonsillectomy pulse therapy versus multiple-drug therapy for IgA nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

7 January 2021

A randomized, placebo-controlled, multicenter trial evaluating alternate-day prednisone and fish oil supplements in young patients with immunoglobulin A nephropathy. Scientific Planning Committee of the IgA Nephropathy Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

7 January 2021

Immunoglobulin a nephropathy with mild renal lesions: a call in the forest for physicians and nephrologists

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

7 January 2021

Eicosapentaenoic acid and IgA nephropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

7 January 2021

Sodium cromoglycate therapy in IgA nephropathy: a preliminary short-term trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

7 January 2021

Controlled trial of antiplatelet agents in mesangial IgA glomerulonephritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

7 January 2021

ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

7 January 2021

Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

7 January 2021

Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

7 January 2021

Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy--is it relevant for adult patients?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

7 January 2021

Effects of angiotensin II blockade on nitric oxide blood levels in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

7 January 2021

Effects of defibrotide treatment in patients with IgA nephropathy and reduced renal function

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

7 January 2021

Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

7 January 2021

Effects of dipyridamole on the short-term evolution of glomerulonephritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

7 January 2021

Omega-3 fatty acid supplementation and lipoprotein(a) concentrations in patients with chronic glomerular diseases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

7 January 2021

Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

7 January 2021

Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

7 January 2021

IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

7 January 2021

Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

7 January 2021

Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

7 January 2021

Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

7 January 2021

Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

7 January 2021

The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

7 January 2021

Beneficial effects of high-dose losartan in IgA nephritis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003962.PUB2

7 January 2021

10.1002/14651858.CD003962.PUB2

Identifiers

DOI

0 references

Fatcat ID

release_closani7nzeqdbs2ekrzcmyqsa

0 references